Jun 8, 2026 07:31AM
Jun 8, 2026 07:30AM
May 26, 2026 07:30AM
May 8, 2026 07:30AM
Apr 28, 2026 07:30AM
Apr 28, 2026 07:30AM
Apr 28, 2026 07:30AM Soligenix Announces Interim Results from the Phase 3 FLASH2 Trial Evaluating HyBryte™ in Treatment of Cutaneous T-Cell Lymphoma
Apr 2, 2026 07:30AM
Apr 2, 2026 07:30AM
Mar 31, 2026 07:32AM
Mar 31, 2026 07:30AM
Mar 26, 2026 07:31AM
Mar 26, 2026 07:30AM
Mar 23, 2026 07:30AM HyBryte™ Treatment Results to be Presented at US Cutaneous Lymphoma Consortium Annual Workshop 2026
Mar 19, 2026 07:30AM
Mar 10, 2026 07:30AM
Mar 10, 2026 07:30AM
Feb 26, 2026 07:32AM
Feb 26, 2026 07:30AM
Feb 24, 2026 07:30AM
Feb 12, 2026 07:31AM Soligenix provides update on late-stage rare disease pipeline
Feb 12, 2026 07:30AM
Dec 18, 2025 07:30AM
Dec 18, 2025 07:30AM
Dec 17, 2025 07:30AM
Dec 17, 2025 07:30AM
Dec 10, 2025 08:30AM
Dec 5, 2025 08:30AM Soligenix Inc. (NASDAQ: SNGX) Advancing Rare-Disease Therapies Positioned at Pivotal Crossroad
Dec 5, 2025 08:30AM
Dec 4, 2025 08:30AM
Dec 3, 2025 08:30AM
Dec 2, 2025 08:30AM
Nov 19, 2025 07:30AM
Nov 19, 2025 07:30AM
Nov 7, 2025 07:30AM Soligenix Announces Recent Accomplishments and Third Quarter 2025 Financial Results
Oct 14, 2025 07:30AM
Oct 14, 2025 07:30AM
Oct 8, 2025 07:00AM
Oct 7, 2025 07:30AM
Oct 7, 2025 07:30AM
Sep 30, 2025 07:30AM
Sep 30, 2025 07:30AM Soligenix Announces Expansion of European Medical Advisory Board for Cutaneous T-Cell Lymphoma
Sep 29, 2025 04:05PM
Sep 29, 2025 04:05PM
Sep 26, 2025 06:34AM
Sep 26, 2025 06:33AM
Sep 23, 2025 07:30AM
Sep 23, 2025 07:30AM
Sep 4, 2025 07:31AM Soligenix vaccine study shows 2-year stability at high temperatures
Sep 4, 2025 07:30AM

323,573 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All